Search
for
Sort by
Research 91–120 of 228
- Cutaneous side-effects of EGFR inhibitors and their management.
- Validation of TrichoScan® technology as a fully-automated tool for evaluation of hair growth parameters
- Cetuximab-Associated Elongation of the Eyelashes
- Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
- Taiwanese Dermatological Association consensus for the prevention and management of epidermal growth factor receptor tyrosine kinase inhibitor-related skin toxicities
- Persistently curly hair phenotype with the use of nivolumab for squamous cell lung cancer
- Novel acquisitions on the immunoprotective roles of the EGF receptor in the skin
- Repigmentation of hair following adalimumab therapy
- Perifollicular Xanthomas Associated with Epidermal Growth Factor Receptor Inhibitor Therapy
- Epidermal field carcinogenesis in bald-headed: An attempt at finetuning early non-invasive detection
- Stated Preferences in Non-Small-Cell Lung Cancer: A Discrete Choice Experiment
- Erosive pustular dermatosis of the scalp induced by gefitinib: case and review of the literature
- Epidermal growth factor receptor inhibitors and hair
- Treatment of Cultured Sebocytes with an EGFR Inhibitor Does Not Lead to Significant Upregulation of Inflammatory Biomarkers
- Eyelash trichomegaly complicating pembrolizumab for colorectal cancer
- Drugs linked to blepharitis, meibomian gland dysfunction, and chalazion: a real-world, population-based pharmacovigilance analysis
- Efficacy and patient-reported outcomes in advanced non-small cell lung cancer patients receiving aumolertinib as first-line therapy: a real-world study
- Drug-Induced Hair Changes
- Alterazioni dei capelli da farmaci
- ODAC Chairs Reveal Challenges, High Drama in a Decade of Service
- Momentary fluke of cyclosporine in incidental repigmentation and hypertrichosis of hair
- Cutaneous Adverse Effects of EGFR Therapy in Breast Cancer Treatment
- Spotlight commentary: Navigating the cutaneous side effects of chemotherapy
- Review of Drug Repositioning in Cancer Therapeutics
- 566 Staphylococcus epidermidis for the topical treatment of epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity
- 422 Human hair follicles express PD-L1, whose expression is down-regulated by EGFR and MEK inhibitors ex vivo. A potential mechanism for EGFR inhibitor induced sterile folliculitis
- 870 Y27632 promotes proliferation via EGFR signaling in a newly isolated and characterized human primary sebocyte cell line
- Folliculitis decalvans: why is there no established treatment?
- First-in-Man Clinical Trial of the Oral Pan-AKT Inhibitor MK-2206 in Patients With Advanced Solid Tumors
- Understanding, recognizing, and managing toxicities of targeted anticancer therapies